MX2022009165A - Anticuerpos contra la integrina alfa v beta 8 para usarse en el tratamiento de la enfermedad renal. - Google Patents
Anticuerpos contra la integrina alfa v beta 8 para usarse en el tratamiento de la enfermedad renal.Info
- Publication number
- MX2022009165A MX2022009165A MX2022009165A MX2022009165A MX2022009165A MX 2022009165 A MX2022009165 A MX 2022009165A MX 2022009165 A MX2022009165 A MX 2022009165A MX 2022009165 A MX2022009165 A MX 2022009165A MX 2022009165 A MX2022009165 A MX 2022009165A
- Authority
- MX
- Mexico
- Prior art keywords
- kidney
- integrin
- kidney disease
- antibodies
- tissue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966258P | 2020-01-27 | 2020-01-27 | |
| PCT/EP2021/051753 WO2021151889A1 (en) | 2020-01-27 | 2021-01-26 | ANTI-αVβ8 INTEGRIN ANTIBODIES FOR USE IN TREATING KIDNEY DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009165A true MX2022009165A (es) | 2022-08-16 |
Family
ID=74561850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009165A MX2022009165A (es) | 2020-01-27 | 2021-01-26 | Anticuerpos contra la integrina alfa v beta 8 para usarse en el tratamiento de la enfermedad renal. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230112035A1 (https=) |
| EP (1) | EP4096785A1 (https=) |
| JP (1) | JP7706458B2 (https=) |
| KR (1) | KR20220132567A (https=) |
| CN (1) | CN115151305A (https=) |
| AR (1) | AR121193A1 (https=) |
| AU (1) | AU2021213403B2 (https=) |
| BR (1) | BR112022014633A2 (https=) |
| CA (1) | CA3167390A1 (https=) |
| CL (1) | CL2022001999A1 (https=) |
| CO (1) | CO2022011661A2 (https=) |
| CR (1) | CR20220392A (https=) |
| EC (1) | ECSP22066085A (https=) |
| IL (1) | IL294814A (https=) |
| MX (1) | MX2022009165A (https=) |
| PH (1) | PH12022551863A1 (https=) |
| TW (1) | TWI854088B (https=) |
| WO (1) | WO2021151889A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11359024B2 (en) | 2018-09-07 | 2022-06-14 | Pfizer Inc. | Anti-AVB8 antibodies and compositions and uses thereof |
| US20260035468A1 (en) | 2022-09-12 | 2026-02-05 | Institut National de la Santé et de la Recherche Médicale | New anti-itgb8 antibodies and its uses thereof |
| TW202446789A (zh) * | 2023-03-31 | 2024-12-01 | 美商建南德克公司 | 抗αｖβ８整合素抗體及使用方法 |
| CN117143241B (zh) * | 2023-10-26 | 2024-02-23 | 迈威(上海)生物科技股份有限公司 | 与人整合素蛋白itgav/itgb8特异性结合的单克隆抗体 |
| CN117126282B (zh) * | 2023-10-26 | 2024-01-12 | 迈威(上海)生物科技股份有限公司 | 抗体及其在制备阻断αvβ8与Latent TGF-β的结合的药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| MX342270B (es) * | 2010-02-18 | 2016-09-21 | The Regents Of The Univ Of California * | ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8. |
| SG2014014237A (en) * | 2011-08-17 | 2014-07-30 | Univ California | Antibodies that bind integrin alpha-v beta-8 |
| US20170073406A1 (en) * | 2014-05-06 | 2017-03-16 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| PT3157561T (pt) | 2014-06-17 | 2020-03-25 | Univ California | Anticorpos contra alfa-v beta-8 melhorados |
| EP3634485A4 (en) * | 2017-06-07 | 2021-07-21 | Silverback Therapeutics, Inc. | CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES |
| CA3112523A1 (en) * | 2018-08-08 | 2020-02-13 | The General Hospital Corporation | Integrin antagonists |
-
2021
- 2021-01-13 TW TW110101209A patent/TWI854088B/zh active
- 2021-01-26 US US17/759,388 patent/US20230112035A1/en active Pending
- 2021-01-26 BR BR112022014633A patent/BR112022014633A2/pt unknown
- 2021-01-26 KR KR1020227028722A patent/KR20220132567A/ko active Pending
- 2021-01-26 JP JP2022545136A patent/JP7706458B2/ja active Active
- 2021-01-26 WO PCT/EP2021/051753 patent/WO2021151889A1/en not_active Ceased
- 2021-01-26 CR CR20220392A patent/CR20220392A/es unknown
- 2021-01-26 CA CA3167390A patent/CA3167390A1/en active Pending
- 2021-01-26 AU AU2021213403A patent/AU2021213403B2/en active Active
- 2021-01-26 IL IL294814A patent/IL294814A/en unknown
- 2021-01-26 CN CN202180010557.1A patent/CN115151305A/zh active Pending
- 2021-01-26 PH PH1/2022/551863A patent/PH12022551863A1/en unknown
- 2021-01-26 EP EP21703839.7A patent/EP4096785A1/en active Pending
- 2021-01-26 MX MX2022009165A patent/MX2022009165A/es unknown
- 2021-01-27 AR ARP210100199A patent/AR121193A1/es unknown
-
2022
- 2022-07-25 CL CL2022001999A patent/CL2022001999A1/es unknown
- 2022-08-18 CO CONC2022/0011661A patent/CO2022011661A2/es unknown
- 2022-08-23 EC ECSENADI202266085A patent/ECSP22066085A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220392A (es) | 2022-09-07 |
| JP7706458B2 (ja) | 2025-07-11 |
| CO2022011661A2 (es) | 2022-08-30 |
| CN115151305A (zh) | 2022-10-04 |
| TW202140554A (zh) | 2021-11-01 |
| JP2023511686A (ja) | 2023-03-22 |
| PH12022551863A1 (en) | 2024-01-03 |
| AU2021213403B2 (en) | 2025-04-10 |
| WO2021151889A1 (en) | 2021-08-05 |
| TWI854088B (zh) | 2024-09-01 |
| KR20220132567A (ko) | 2022-09-30 |
| ECSP22066085A (es) | 2022-09-30 |
| CA3167390A1 (en) | 2021-08-05 |
| EP4096785A1 (en) | 2022-12-07 |
| AU2021213403A1 (en) | 2022-09-15 |
| BR112022014633A2 (pt) | 2022-09-13 |
| AR121193A1 (es) | 2022-04-27 |
| IL294814A (en) | 2022-09-01 |
| CL2022001999A1 (es) | 2023-01-27 |
| US20230112035A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009165A (es) | Anticuerpos contra la integrina alfa v beta 8 para usarse en el tratamiento de la enfermedad renal. | |
| EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
| CL2020002446A1 (es) | Anticuerpos contra mica y/o micb y sus usos | |
| MX2022004343A (es) | Anticuerpos modificados genéticamente como degradadores moleculares a través de receptores celulares. | |
| CO6341486A2 (es) | Tratamiento y profilaxis de amiloidosis | |
| GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
| EA200901211A1 (ru) | Антигены белка с5 и их применение | |
| EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
| CO6390041A2 (es) | Agentes y antagonistas fijaodres de notch y metodos para el uso de los mismos. | |
| WO2008137901A8 (en) | Methods for treating and preventing gi syndrome and graft versus host disease | |
| EA201370081A1 (ru) | Антитела к cd48 и их применение | |
| EA201590144A1 (ru) | Rspo3-связывающие агенты и их применение | |
| EA201070740A1 (ru) | Способ лечения перелома кости антителами против склеростина | |
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| SA523440622B1 (ar) | أجسام مضادة | |
| EA201790563A1 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
| EA201591522A1 (ru) | Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов | |
| AR082353A1 (es) | Ligando ox40 y de linfopoyetina del estroma timico (tslp) en el cancer | |
| EA202193111A1 (ru) | Композиции и способы для лечения рака | |
| MX2024008740A (es) | Anticuerpo humanizado que tiene especificidad de union por la integrina \03b14\03b27 humana para usarse en la prevencion de la enfermedad del injerto contra huesped de grado iii o iv. | |
| MX2019013137A (es) | Metodos y composiciones para tratar enfermedades oculares alergicas. | |
| MX2023001881A (es) | Tratamiento con ribitol. | |
| BR112023024701A2 (pt) | Métodos de tratamento de doenças do fígado | |
| MX421623B (es) | Composiciones para tratar enfermedades pulmonares crónicas | |
| WO2021044405A3 (en) | Therapeutic apoptotic cells for treatment of osteoarthritis |